While Crohn’s disease affects only 1.3% of the US population, it can cause severe and life-threatening complications.
Crohn’s disease, also known as inflammatory bowel disease, is a condition that damages the lining of your digestive tract. It can cause abdominal pain, diarrhea, and weight loss. Each person is affected differently by Crohn’s disease. It can be found in different parts of the digestive system and can cause severe pain and inflammation.
Crohn’s disease is not curable. The treatment is usually with anti-inflammatory drugs and therapy. This can lead to long-term relief. This often debilitating condition is still being researched and treated by investigatory clinical research (ICR). The ICR team of doctors and researchers are constantly involved in treatment studies.
Crohn’s disease, a progressive chronic disease, is being studied more and more. Researchers and doctors need to understand the disease in order to find new therapies. For example, Filgotinib testing is a possibility. Filgotinib is a medication that is frequently prescribed to treat rheumatoid arthritis. Filgotinib’s anti-inflammatory properties make it an attractive candidate for research. It is also showing promise to reduce inflammation and remission Crohn’s disease.
ICR is just one of many research organizations that devote a lot of their resources to the relief and elimination of Crohn’s disease symptoms. ICR uses volunteers aged 18 to 75 to carry out their research. The study is open to both males and females who are not pregnant and have never been diagnosed.
Filgotinib is being used by patients suffering from Crohn’s disease. It is crucial to understand how this drug and its anti-inflammatory properties impact all five forms of Crohn’s disease. The five forms of Crohn’s disease are Gastroduodenal Crohn’s disease (ileitis), ileitis and Jejunoileitis. ICR must learn how each treatment affects each form of Crohn’s disease to be able to fully understand the disease. www.icrmd.com is the place to go if you have any questions or would like to participate in the study.